Manage your account, request prescriptions, set up appointments & more.

Don't have an account
Contact Us



Clinical Trial Title


Trial Status

Open to Enrollment

Start Date

July 24, 2017


Trial Type

Cancer (Oncology)

Specific Condition



Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Eligibility Criteria

  • Histologically proven diagnosis of glioblastoma (WHO grade IV) confirmed by central review prior to step 2 registration
  •     Diagnosis must be made by surgical excision, either partial or complete. Stereotactic biopsy and cavitronic ultrasonic surgical (CUSA) techniques are not allowed
  • Age ≥ 18
  • Karnofsky performance status ≥ 70 within 28 days
  • Tumor tissue that is determined by central pathology review
  • History/physical examination within 28 days
  • The patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days
  • Documentation of steroid doses within 28 days
Ineligibility Criteria
  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years
  • Recurrent or multifocal malignant gliomas
  • Any site of distant disease
  • Prior chemotherapy or radiosensitizers for cancers of the head and neck region
  • Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted
  • Prior radiotherapy to the head or neck

Please contact Legacy Oncology Research for additional study inclusion/exclusion information.

IRB Number

Central IRB

Principal Investigator Name

Andrew Kee, MD

Contact Name

Oncology Clinical Research



Contact Fax


Contact E-Mail

Last Updated: Thursday, December 28, 2017 11:31:24 AM